Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose-escalation and dose-expansion study of intravitreal FT-003 in neovascular age-related macular degeneration
CTR20232397Phase 2Active
- Sponsor
- Frontera Therapeutics
- Start
- Aug 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of FT-003 in exudative macular degeneration, sponsored by Frontera Therapeutics. Started Aug 2023; status: active.
02
Drugs
FT-003
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20232397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232397.